Alector, Inc. Research and Development Expense
Alector, Inc. (ALEC) reported Research and Development Expense of $19.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Alector, Inc. research and development expense for the quarter ending 2026-06-30 was $19.46M, a 29.52% decline year-over-year.
- Alector, Inc. research and development expense for the quarter ending 2026-03-31 was $17.86M, a 46.92% decline year-over-year.
- Alector, Inc. research and development expense for the quarter ending 2025-12-31 was $32.46M, a 30.13% decline year-over-year.
- Alector, Inc. research and development expense for the quarter ending 2025-09-30 was $29.35M, a 38.85% decline year-over-year.
- Alector, Inc. research and development expense for fiscal 2025 was $123.06M, a 33.81% decline from fiscal 2024.
- Alector, Inc. research and development expense for fiscal 2024 was $185.94M, a 3.21% decline from fiscal 2023.
- Alector, Inc. research and development expense for fiscal 2023 was $192.12M, a 8.70% decline from fiscal 2022.
- Alector, Inc. research and development expense for fiscal 2022 was $210.42M, a 11.09% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.46M 10-Q · filed 2026-08-06 | $37.32M 10-Q · filed 2026-08-06 | $69.78M derived: sum of 3 quarters · filed 2026-08-06 | $99.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $17.86M 10-Q · filed 2026-05-07 | $50.32M derived: sum of 2 quarters · filed 2026-05-07 | $79.67M derived: sum of 3 quarters · filed 2026-05-07 | $107.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $32.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $61.81M derived: sum of 2 quarters · filed 2026-02-25 | $89.42M derived: sum of 3 quarters · filed 2026-08-06 | $123.06M 10-K · filed 2026-02-25 |
| 2025-09-30 | $29.35M 10-Q · filed 2025-11-06 | $56.96M derived: sum of 2 quarters · filed 2026-08-06 | $90.60M 10-Q · filed 2025-11-06 | $137.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $27.61M 10-Q · filed 2026-08-06 | $61.25M 10-Q · filed 2026-08-06 | $107.71M derived: sum of 3 quarters · filed 2026-08-06 | $155.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $33.64M 10-Q · filed 2026-05-07 | $80.10M derived: sum of 2 quarters · filed 2026-05-07 | $128.10M derived: sum of 3 quarters · filed 2026-05-07 | $174.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $46.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $94.46M derived: sum of 2 quarters · filed 2026-02-25 | $140.77M derived: sum of 3 quarters · filed 2026-02-25 | $185.94M 10-K · filed 2026-02-25 |
| 2024-09-30 | $48.00M 10-Q · filed 2025-11-06 | $94.31M derived: sum of 2 quarters · filed 2025-11-06 | $139.48M 10-Q · filed 2025-11-06 | $187.20M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $46.31M 10-Q · filed 2025-08-07 | $91.48M 10-Q · filed 2025-08-07 | $139.20M derived: sum of 3 quarters · filed 2025-08-07 | $185.53M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $45.17M 10-Q · filed 2025-05-08 | $92.89M derived: sum of 2 quarters · filed 2025-05-08 | $139.22M derived: sum of 3 quarters · filed 2025-05-08 | $185.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $47.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $94.05M derived: sum of 2 quarters · filed 2025-02-26 | $140.23M derived: sum of 3 quarters · filed 2025-02-26 | $192.12M 10-K · filed 2025-02-26 |
| 2023-09-30 | $46.33M 10-Q · filed 2024-11-06 | $92.50M derived: sum of 2 quarters · filed 2024-11-06 | $144.39M 10-Q · filed 2024-11-06 | $198.88M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $46.18M 10-Q · filed 2024-08-07 | $98.06M 10-Q · filed 2024-08-07 | $152.56M derived: sum of 3 quarters · filed 2025-02-26 | $200.91M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $51.89M 10-Q · filed 2024-05-08 | $106.38M derived: sum of 2 quarters · filed 2025-02-26 | $154.73M derived: sum of 3 quarters · filed 2025-02-26 | $209.26M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $54.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $102.84M derived: sum of 2 quarters · filed 2025-02-26 | $157.38M derived: sum of 3 quarters · filed 2025-02-26 | $210.42M 10-K · filed 2025-02-26 |
| 2022-09-30 | $48.35M 10-Q · filed 2023-11-07 | $102.88M derived: sum of 2 quarters · filed 2023-11-07 | $155.93M 10-Q · filed 2023-11-07 | $208.72M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $54.53M 10-Q · filed 2023-08-03 | $107.58M 10-Q · filed 2023-08-03 | $160.37M derived: sum of 3 quarters · filed 2024-02-27 | $203.43M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $53.04M 10-Q · filed 2023-05-04 | $105.83M derived: sum of 2 quarters · filed 2024-02-27 | $148.90M derived: sum of 3 quarters · filed 2024-02-27 | $196.72M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $52.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $95.86M derived: sum of 2 quarters · filed 2024-02-27 | $143.67M derived: sum of 3 quarters · filed 2024-02-27 | $189.41M 10-K · filed 2024-02-27 |
| 2021-09-30 | $43.07M 10-Q · filed 2022-11-08 | $90.88M derived: sum of 2 quarters · filed 2022-11-08 | $136.62M 10-Q · filed 2022-11-08 | $181.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $47.82M 10-Q · filed 2022-08-04 | $93.55M 10-Q · filed 2022-08-04 | $137.93M derived: sum of 3 quarters · filed 2023-02-28 | $181.75M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $45.73M 10-Q · filed 2022-05-05 | $90.12M derived: sum of 2 quarters · filed 2023-02-28 | $133.94M derived: sum of 3 quarters · filed 2023-02-28 | $168.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $44.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $88.20M derived: sum of 2 quarters · filed 2023-02-28 | $122.26M derived: sum of 3 quarters · filed 2023-02-28 | $156.87M 10-K · filed 2023-02-28 |
| 2020-09-30 | $43.82M 10-Q · filed 2021-11-04 | $77.88M derived: sum of 2 quarters · filed 2021-11-04 | $112.49M 10-Q · filed 2021-11-04 | $138.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $34.06M 10-Q · filed 2021-08-03 | $68.67M 10-Q · filed 2021-08-03 | $94.43M derived: sum of 3 quarters · filed 2022-02-24 | $122.95M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $34.60M 10-Q · filed 2021-05-05 | $60.37M derived: sum of 2 quarters · filed 2022-02-24 | $88.89M derived: sum of 3 quarters · filed 2022-02-24 | $114.53M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $25.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $54.28M derived: sum of 2 quarters · filed 2022-02-24 | $79.92M derived: sum of 3 quarters · filed 2022-02-24 | $100.53M 10-K · filed 2022-02-24 |
| 2019-09-30 | $28.52M 10-Q · filed 2020-11-10 | $54.16M derived: sum of 2 quarters · filed 2020-11-10 | $74.77M 10-Q · filed 2020-11-10 | $98.86M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $25.64M 10-Q · filed 2020-08-11 | $46.25M 10-Q · filed 2020-08-11 | $70.34M derived: sum of 3 quarters · filed 2021-02-25 | $90.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $20.61M 10-Q · filed 2020-05-13 | $44.70M derived: sum of 2 quarters · filed 2021-02-25 | $65.10M derived: sum of 3 quarters · filed 2021-02-25 | $81.91M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $44.49M derived: sum of 2 quarters · filed 2021-02-25 | $61.31M derived: sum of 3 quarters · filed 2021-02-25 | $73.03M 10-K · filed 2021-02-25 |
| 2018-09-30 | $20.39M 10-Q · filed 2019-11-12 | $37.21M derived: sum of 2 quarters · filed 2019-11-12 | $48.93M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $16.82M 10-Q · filed 2019-08-12 | $28.54M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $11.72M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $29.91M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |